Findings indicate that the genetic deletion of MD2 significantly reduces the inflammatory injury and fibrosis in a methionine‐choline deficiency mouse model of NASH 14, further supporting the MD2‐TLR4 pathway as an underlying pathogenic mechanism. The gene discussed is LY96; the disease is metabolic dysfunction-associated steatohepatitis.